Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry
Victoria Tea(Assistance Publique – Hôpitaux de Paris), Chekrallah Chamandi(Hôpital Européen Georges-Pompidou), Étienne Puymirat(Inserm), Jean Ferrières(Université Fédérale de Toulouse Midi-Pyrénées), François Schiele(Hôpital Saint-Jacques), Nicolas Danchin(Assistance Publique – Hôpitaux de Paris), Guillaume Cayla(Centre Hospitalier Universitaire de Nîmes), Denis Angoulvant(Université de Tours), Tabassome Simon(Sorbonne Université), Thibault Lhermusier(Hôpital Rangueil), Marc P. Bonaca(The Medical Center of Aurora), Marie‐Christine Iliou(Université Paris Cité), Nadia Aïssaoui(Université Paris Cité)
Cited by 16
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k
Rivaroxaban in Peripheral Artery Disease after Revascularization
|New England Journal of Medicine|2020|966
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
|New England Journal of Medicine|2012|941